Literature DB >> 22000405

Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.

Grigoris T Gerotziafas, Hela Baccouche, Mouna Sassi, Vassiliki Galea, Mourad Chaari, Mohamed Hatmi, Meyer M Samama, Ismail Elalamy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22000405     DOI： 10.1016/j.thromres.2011.09.004

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  6 in total

Review 1.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

Review 2.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 3.  Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.

Authors:  Alexander Gg Turpie
Journal:  Ther Clin Risk Manag       Date:  2014-03-22       Impact factor: 2.423

4.  Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits.

Authors:  Lu Yin; Yuan Qi; Zhiru Ge; Jiajin Li
Journal:  Open Life Sci       Date:  2022-01-28       Impact factor: 0.938

Review 5.  Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

Authors:  Lina Khider; Nicolas Gendron; Laetitia Mauge
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

Review 6.  New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients.

Authors:  Grigoris T Gerotziafas; Isabelle Mahé; Ismail Elalamy
Journal:  Ther Clin Risk Manag       Date:  2014-06-13       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.